Not long ago an HIV/AIDS diagnosis was considered a death sentence. Today, thanks to advances in biopharmaceutical research, we are radically altering the trajectory of HIV/AIDS and helping millions live longer, fuller and more productive lives.
Since the approval of anti-retroviral treatments in 1995, death rates are down by 80%.
With the treatment protocols currently available, a 20-year-old diagnosed today can expect to live a full life. In fact, in the last 25 years, HIV/AIDS fell from the 7th to the 23rd leading cause of death in the U.S.
Ongoing research projects by leading biopharmaceutical companies stand to further improve quality of life and longevity of HIV/AIDS patients. But the key to survival, both now and in the future, is providing patients access to the latest available treatments.